Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy

• Published in: The Journal of urology Vol. 203; no. 5; pp. 940 - 948
• Main Authors: Pouliot, Frédéric, Rouleau, Mélanie, Neveu, Bertrand, Toren, Paul, Morin, Fannie, Vélot, Lauriane, Ding, Keyue, Caron, Patrick, Lacombe, Louis, Lévesque, Éric, Klotz, Laurence, Guillemette, Chantal
• Format: Journal Article
• Language: English
• Published: United States 01-05-2020
• Subjects: Anabolic Agents - pharmacology; Androgens - pharmacology; Androstenedione - pharmacology; Biomarkers, Tumor - metabolism; Castration - methods; Cell Line, Tumor; Follow-Up Studies; Humans; Male; Mass Spectrometry; Neoplasm Recurrence, Local - metabolism; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - therapy; Prospective Studies; Prostate - drug effects; Prostate - metabolism; Prostate - pathology; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Receptors, Androgen - drug effects; Receptors, Androgen - metabolism; Testosterone - analogs & derivatives; Testosterone - pharmacology; Time Factors; mass spectrometry; androgen; steroids; luminescence; receptors; prostatic neoplasms
• ISSN: 0022-5347; 1527-3792
• DOI: 10.1097/JU.0000000000000699

Beyond testosterone, several steroids contribute to the activation of the androgen receptor pathway, but their relative contributions to the activation of the androgen receptor signaling axis in patients with castrated prostate cancer remain unknown.
Serum levels of 9 steroids were measured by mass spectrometry from continuously castrated patients of the PR.7 study (219) and from the PCA24 cohort (116). For each steroid standard curves for dose dependent prostate specific antigen promoter activation were built in castration sensitive (LAPC4) and resistant (VCaP) prostate cancer models. Standard curves were used to determine the androgen receptor activation potency for each steroid measurement from patients in these trials.
In LAPC4 and VCaP cells testosterone, dihydrotestosterone and androstenedione induced androgen receptor transcriptional activity, while dehydroepiandrosterone, 5alpha-androstan-3beta,17beta-diol, androstenediol and androsterone stimulated androgen receptor only in VCaP cells. Extragonadal steroids were responsible for 34% (LAPC4) and 88% (VCaP) of the serum total androgen receptor transcriptional activity found in castrated cases. The total androgen receptor transcriptional activity secondary to testosterone, dihydrotestosterone and androstenedione was associated with time to castration resistance in patients from the PR.7 study (HR 2.17, 95% CI 1.12-4.23, p=0.02) in multivariate analysis using the castration sensitive model (LAPC4). Androgen receptor transcriptional activity of extragonadal androstenedione was the only steroid statistically associated with time to castration resistance in univariate analysis (HR 1.89, 95% CI 1.04-3.44, p=0.036).
Extragonadal steroids contribute significantly to the androgen receptor axis activation at castration levels of testosterone in recurrent nonmetastatic prostate cancer and these sustain the development of castration resistance after primary local treatment.